Kidney Care Access Protection Act
- Bill Number
- S. 2730
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-08: Read twice and referred to the Committee on Finance.
- Last Updated
- 2026-03-25T11:03:19Z
AI-Generated Summary
Purpose of the Legislation
The Kidney Care Access Protection Act aims to enhance Medicare coverage and payment mechanisms for innovative treatments related to end-stage renal disease (ESRD), a severe kidney condition requiring dialysis or transplant. It seeks to ensure patients have better access to new drugs, biological products (such as proteins or antibodies used in treatment), and equipment by extending and refining payment adjustments, while also stabilizing payments to address staffing and cost forecasting issues in dialysis facilities.
Key Provisions
- Extension and Refinement of Payment Adjustments for New Drugs and Biologicals (Section 101(a) and (b)):
- Extends the Transitional Drug Add-on Payment Adjustment (TDAPA)—a temporary extra payment for new renal dialysis drugs or biologicals approved by the FDA after January 1, 2020—to at least three years for items furnished starting January 1, 2026.
- Introduces a permanent add-on adjustment to the base payment rate after TDAPA ends, calculated based on recent utilization data, average sales price (or alternatives like wholesale acquisition cost if sales data is unavailable), and set at 65% of the computed amount. This adjustment updates annually for inflation and applies immediately after TDAPA, without reducing overall Medicare spending (not "budget neutral") or adjusting for patient-specific factors like age or health complexity.
- Clarification of Renal Dialysis Services (Section 101(c)):
- Updates the definition to exclude certain new drugs or biologicals (approved after December 31, 2025) used for co-occurring conditions (e.g., heart disease, inflammation, cancer, diabetes, obesity) that are not directly replacing existing dialysis-covered items. Claims for these must include a specific billing code (AY modifier) for proper payment under Medicare Part B.
- Updates to Payments for New Equipment and Supplies (Section 101(d)):
- Extends the Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES) to at least three years for qualifying devices furnished starting January 1, 2026.
- Makes "breakthrough devices" (FDA-designated for fast-track development and review due to significant patient benefits) eligible for TPNIES.
- Allows inclusion of capital-related assets (e.g., expensive machinery) in these payments, removing prior exclusions.
- Medicare Advantage Integration (Section 102):
- Requires Medicare Advantage (MA) plans—private alternatives to traditional Medicare—to make direct add-on payments to dialysis providers for new drugs, biologicals, or equipment, matching the amounts and duration under the traditional ESRD Prospective Payment System (ESRD PPS, a bundled payment method for dialysis services).
- Forecast Error Adjustment for Payment Updates (Section 201):
- Adds a correction to the annual ESRD PPS payment increase (based on a "market basket" of goods and services costs, including labor) starting in 2026. This accounts for forecasting errors if the predicted vs. actual price changes differ by more than 0.5 percentage points, using cumulative data from 2021–2022 initially and recent years thereafter. This aims to stabilize payments amid staffing shortages.
All changes take effect January 1, 2026, for services furnished on or after that date.
Significant Changes to Existing Law
- Extensions and Permanence: Previously, TDAPA and TPNIES lasted up to two years; this bill extends them to at least three years and adds a permanent post-TDAPA adjustment, ensuring ongoing reimbursement for innovations beyond temporary periods.
- Exclusions and Billing: Introduces specific exclusions for new comorbid treatments in the renal dialysis services definition and mandates a billing modifier, clarifying what qualifies for bundled ESRD payments vs. separate Part B coverage.
- Breakthrough Devices and Capital Assets: Expands TPNIES eligibility to FDA breakthrough devices and removes barriers for capital investments, which were previously ineligible.
- Medicare Advantage Alignment: MA plans were not required to mirror ESRD PPS add-ons; this mandates direct payments, closing a gap in coverage consistency.
- Forecast Error Mechanism: Adds a new subclause to the market basket labor adjustment in the Social Security Act, introducing forecast error corrections to prevent under- or over-payments due to inaccurate cost predictions.
Potential Impacts
- On Government Agencies: The U.S. Department of Health and Human Services (HHS), via the Centers for Medicare & Medicaid Services (CMS), will face increased administrative burdens to calculate, implement, and update add-on payments, potentially raising Medicare expenditures without budget neutrality. This could strain federal budgets but promote long-term efficiency in kidney care.
- On Citizens: ESRD patients (over 500,000 Medicare beneficiaries) gain improved access to cutting-edge treatments, potentially leading to better health outcomes and reduced complications from comorbidities. However, it may indirectly increase Medicare premiums or taxes if costs rise.
- On International Relations: Minimal direct impact, though it could encourage U.S. pharmaceutical and device manufacturers to prioritize FDA approvals for renal innovations, indirectly affecting global supply chains for these products.
Main Stakeholders Affected
- ESRD Patients: Primary beneficiaries, with enhanced access to new therapies.
- Dialysis Facilities and Providers: Receive extended and permanent payments, aiding adoption of innovations and staffing amid labor shortages.
- Pharmaceutical and Device Manufacturers: Benefit from longer reimbursement periods, incentivizing R&D for renal products.
- Medicare Advantage Plans: Must align payments with traditional Medicare, potentially increasing their costs but ensuring equitable coverage.
- Taxpayers and Medicare Program: Bear higher spending on kidney care without offsets.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens Medicare's bundled payment system under the Social Security Act by embedding innovation protections, reducing disputes over transitional payments. The non-budget-neutral clause may invite legal challenges if it significantly impacts federal spending, but it aligns with congressional authority over entitlements.
- Constitutional: No apparent issues; it exercises Congress's spending power under Article I without infringing on states or individual rights.
- Political: Bipartisan sponsorship (Senators Blackburn and Booker) signals broad support for kidney care amid rising chronic disease rates. It addresses industry concerns (e.g., from dialysis chains like DaVita) about innovation stifling due to short payment windows, but critics may highlight added costs to the Medicare Trust Fund, potentially fueling debates on healthcare affordability.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Booker, Cory A. [D-NJ], Sen. Cassidy, Bill [R-LA]
Recent Actions
- 2025-09-08: Read twice and referred to the Committee on Finance.
- 2025-09-08: Introduced in Senate
Bill Versions
- Kidney Care Access Protection Act — issued 2025-09-08 — PDF (12 pages)